
Results
9
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
9 companies
AbbVie
Market Cap: US$438.2b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$244.78
7D
-3.9%
1Y
31.3%
Merck
Market Cap: US$306.3b
Operates as a healthcare company worldwide.
MRK
US$120.78
7D
-6.3%
1Y
48.2%
Travere Therapeutics
Market Cap: US$5.2b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$57.06
7D
-1.4%
1Y
248.4%
Mesa Laboratories
Market Cap: US$524.6m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$94.64
7D
-1.6%
1Y
22.0%
Sotera Health
Market Cap: US$5.1b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$17.77
7D
1.7%
1Y
58.2%
SIGA Technologies
Market Cap: US$258.9m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$3.42
7D
-6.8%
1Y
-49.0%
BioLife Solutions
Market Cap: US$1.4b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$28.65
7D
2.6%
1Y
37.9%
Waters
Market Cap: US$36.6b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$376.39
7D
0.4%
1Y
30.0%
Repligen
Market Cap: US$8.2b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$147.13
7D
5.2%
1Y
24.6%